According to the article, the authors have described a new method that simplified the total cavopulmonary connection without surgical approach using two separate polytetrafluoroethylene (PTFE) grafts. The two grafts have been divided by autologous pericardium to close the top end of the inferior PTFE graft resulting in a stump above the level of fenestration. In the presence that stump, wouldn't the likelihood of clot formation and TE, which is a possibility that should never be ignored, increase, especially in the presence of large connection between right and left atrium? What kind of anticoagulation should we use to prevent clot formation? We read with interest the comments regarding anticoagulation for an interventional extracardiac Fontan by Saritas et al and acknowledge the omission in our article "A Simplified Technique for Interventional Extracardiac Fontan." 1 The isolated upper segment of the extracardiac conduit has a larger diameter than the bidirectional cavopulmonary connection and is anastomosed to the inferior surface of the right pulmonary artery with an offset. Consequently, some flow from the right bidirectional cavopulmonary shunt will be directed into this segment and should theoretically prevent thrombus formation.
The covered stent deployed during the interventional Fontan should be sited entirely within the extracardiac conduit and should not protrude into the right pulmonary artery. This will minimize the thromboembolic risk in the pulmonary artery. We use a similar anticoagulation strategy for thromboembolic prophylaxis for a stent in the pulmonary circulation that has been previously described. 2 Thromboembolism is a major cause for morbidity and mortality after the Fontan. Aspirin is our institutional preference for thromboembolic prophylaxis as has been previously reported. [3] [4] [5] A multivariate analysis by Potter et al demonstrated no difference in the incidence of thromboembolic events between the two treatment strategies. 3 Jacobs et al retrospectively analyzed 72 patients (65 lateral atrial tunnel and 7 extracardiac Fontan) who received only aspirin (81 mg/d), none of whom had any thromboembolic events, bleeding episodes, or aspirin-related complications at a mean follow-up of 40 months. 4 A recent propensity score analysis of 475 patients from the Australia and New Zealand Fontan Registry (which included patients from our center) demonstrated no difference in the hazard rates of late thromboembolic events between aspirin and warfarin beyond the first year after the extracardiac Fontan.
